

4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial fo⦠read more
Healthcare
Biotechnology
5 years
USD
Exclusive to Premium users
$10.09
Price-0.89%
-$0.09
$527.467m
Small
-
Premium
Premium
-2189.2%
EBITDA Margin-2256.6%
Net Profit Margin-2235.8%
Free Cash Flow Margin-2189.2%
EBITDA Margin-2256.6%
Net Profit Margin-2235.8%
Free Cash Flow Margin$88.242m
+3.6%
1y CAGR+76699.4%
3y CAGR+57665.2%
5y CAGR-$160.897m
-14.8%
1y CAGR-20.5%
3y CAGR-13.8%
5y CAGR-$2.66
-9.9%
1y CAGR-2.2%
3y CAGR+2.7%
5y CAGR$451.836m
$512.905m
Assets$61.069m
Liabilities$20.535m
Debt4.0%
-0.1x
Debt to EBITDA-$130.055m
-19.2%
1y CAGR-24.7%
3y CAGR-13.5%
5y CAGR